Status:
RECRUITING
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
Lead Sponsor:
Integrative Skin Science and Research
Conditions:
Rosacea
Systemic Inflammation
Eligibility:
All Genders
30-70 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.
Detailed Description
Rosacea is a chronic inflammatory condition that widely prevalent in the general population and is associated with both inflammation and dysfunction of the skin barrier. Gut dysfunction has been shown...
Eligibility Criteria
Inclusion
- Males and females 30 to 70 years of age
- The presence of mild to moderate rosacea (erythematotelangiectatic or papulopustular)
- High sensitivity C-reactive protein (hs-CRP) that is greater than or equal to 1.0 mg/L
Exclusion
- The presence of severe rosacea as noted by the investigator global assessment.
- Those who are unwilling to discontinue oral supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment.
- Discontinuation of oral L-glutamine or L-glutamine containing supplement 1 month prior to enrollment
- Those who are unwilling to discontinue topical benzoyl peroxide or retinoids for 2 weeks prior to enrollment.
- Those who are unwilling to keep their facial regimen the same throughout the study.
- Individuals who have been on an oral antibiotic within the previous one month.
- Individuals who are pregnant or breastfeeding.
- Individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study.
- Individuals on oral contraceptive pills or progesterone or estrogen containing therapies.
- Use of isotretinoin within the three months prior to enrollment.
- Individuals on finasteride or dutasteride
- Current tobacco smoker, smoker within the past year, or greater than 5 pack-year tobacco smoking history.
Key Trial Info
Start Date :
November 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06072066
Start Date
November 22 2023
End Date
December 31 2024
Last Update
August 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Integrative Skin and Research
Sacramento, California, United States, 95815